Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ZL-1218

Monoclonal antibody · Kills target cells, directed at C-C chemokine receptor 8 (CCR8) · developed by Zai Lab

Phase 1 Most advanced trial (none active)
ZLAB Developer
1 Registered trials

What is ZL-1218?

ZL-1218 is a humanized IgG1 monoclonal antibody that binds CCR8 on tumor-infiltrating regulatory T-cells in the tumor microenvironment. It depletes these cells through antibody-dependent cellular cytotoxicity and is being studied in malignant solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
C-C chemokine receptor 8 (CCR8)
Mechanism
Kills target cells, directed at C-C chemokine receptor 8 (CCR8)
Pathways
antibody-dependent cellular cytotoxicity, tumor immunosuppression
Therapy area
Oncology
Developer
Zai Lab, Ltd. (ZLAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05859464 Phase 1 Malignant Solid Tumor Terminated ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Malignant Solid Tumor

Other drugs acting on CCR8

More from Zai Lab

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.

Follow ZLAB, the company behind ZL-1218

See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZLAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.